FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de peptides

Thymalin

Thymaline / Thymic Peptide Extract

Immune & Thymic

Thymalin (also known as Thymic Peptide Extract or Thymalin) is a polypeptide complex extracted from calf thymus glands, developed by Professors Vladimir Khavinson and Vyacheslav Morozov at the St. Petersburg Institute of Bioregulation and Gerontology as an immunomodulatory bioregulator. It was one of the earliest bioregulator peptides investigated for anti-aging applications, with research spanning over 40 years in Russian gerontological medicine. Thymalin is administered via intramuscular injection and targets restoration of thymic function and T-cell immunity that declines with age.

Mécanisme d'action

Bovine thymus extract containing a mixture of thymic peptide factors. Restores T-cell immunity, promotes thymic regeneration, and modulates immune system homeostasis. Part of the Khavinson bioregulator family targeting the thymus and immune system.

Protocoles de recherche

Pour des fins de recherche uniquement. Pas de conseil médical.

Khavinson protocols use 5-10mg intramuscularly daily for 5-10 day cycles, repeated every 6-12 months. Some protocols use sublingual or oral administration at 10-20mg daily.

Notes de recherche

Clinical Research Status

Thymalin has been studied in longitudinal clinical trials spanning over 15 years in elderly populations, with Khavinson's landmark study demonstrating a 46% reduction in mortality over a 12-year follow-up period in treated versus control groups. It is registered as a pharmaceutical preparation in Russia for immunodeficiency states and as an adjuvant in cancer treatment. While these results are remarkable, they have not been independently replicated in Western research settings or subjected to rigorous international peer review standards.

Key Published Findings

The most cited study showed that combined Thymalin and Epithalon treatment in elderly patients (60-80 years) reduced mortality, improved immune function, and normalized neuroendocrine regulation over 6-12 years of observation. Immunological research demonstrates restoration of T-cell subpopulation ratios, increased natural killer cell activity, and normalization of cytokine profiles in immunocompromised elderly patients. Animal studies in various species show increased lifespan, improved tumor resistance, and restoration of thymic architecture following Thymalin administration.

Safety Profile

Thymalin has been used clinically in Russia for decades with a well-established safety profile showing minimal adverse effects at standard therapeutic doses. The most commonly reported side effects are mild injection site reactions and occasional allergic responses in individuals sensitive to bovine-derived products. As an animal-derived extract, theoretical concerns about prion contamination exist, though no cases have been reported in the published literature.

Comparison to Related Compounds

Thymalin differs from synthetic thymic peptides like Thymosin Alpha-1 (Zadaxin) in that it is a complex mixture of multiple thymic peptides rather than a single defined molecule. Compared to the synthetic thymic dipeptide Thymogen (Glu-Trp), Thymalin contains a broader range of immunoactive components but has less molecular specificity. Thymalin's multi-component nature is considered both an advantage (multiple synergistic mechanisms) and a limitation (difficult to standardize and characterize) compared to single-peptide approaches.

Community Observations

Users in the longevity community often use Thymalin as part of seasonal immune optimization protocols, particularly during winter months or periods of high infection risk. Many combine it with Epithalon in what is sometimes called the "Khavinson protocol" for comprehensive anti-aging effects targeting both immune function and cellular longevity. The requirement for intramuscular injection and limited sourcing options outside Russia present practical barriers for many interested users.

Moitié de vie

~Variable (mixture)

Réconstitution

Sterile saline or bacteriostatic water for injection

Conservation

Lyophilisé

Refrigerate 2-8C.

Réconstitué

Use within 24 hours of reconstitution.

Statut légal aux États-Unis

Research chemical (approved in Russia)

Autres noms connus

ThymalineThymic Peptide Extract

Questions fréquentes

Qu'est-ce que Thymalin ?

Thymalin (also known as Thymic Peptide Extract or Thymalin) is a polypeptide complex extracted from calf thymus glands, developed by Professors Vladimir Khavinson and Vyacheslav Morozov at the St. Petersburg Institute of Bioregulation and Gerontology as an immunomodulatory bioregulator. It was one of the earliest bioregulator peptides investigated for anti-aging applications, with research spanning over 40 years in Russian gerontological medicine. Thymalin is administered via intramuscular injection and targets restoration of thymic function and T-cell immunity that declines with age.

Comment agit Thymalin ?

Bovine thymus extract containing a mixture of thymic peptide factors. Restores T-cell immunity, promotes thymic regeneration, and modulates immune system homeostasis. Part of the Khavinson bioregulator family targeting the thymus and immune system.

Quel est le statut réglementaire de Thymalin aux États-Unis ?

Research chemical (approved in Russia)

Quelle est la demi-vie de Thymalin ?

~Variable (mixture)

Sous quels autres noms Thymalin est-il connu ?

Thymaline, Thymic Peptide Extract

Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.

Lire la déclaration complète